A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer

NCT07735377 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: SHR-6914

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.